Connect with us
Advertisement
Oando
Advertisement
Alpha
Advertisement
Hotflex
Advertisement
Binance
Advertisement
Advertisement
UBA
Advertisement
Patricia
Advertisement
Access bank
Advertisement
app

Coronavirus

China publicly presents its COVID-19 vaccines, 2 doses to cost below $146

The vaccine candidates produced by two Chinese companies were on display at a Beijing trade.

Published

on

Covid-19: AstraZeneca vaccine gets huge boost, produces immune response in elderly, Vaccine, COVID-19: Russia to roll out vaccine in September ahead of the West 

China has publicly presented its homegrown covid-19 vaccines for the first time, as the country where the virus was first discovered, looks to shape the narrative surrounding the pandemic.

A lot of high hopes hang on the vaccine candidates produced by Chinese companies, Sinovac Biotech and Sinopharm which are on display at a Beijing trade fair this week.

Although none of these vaccine candidates has hit the market, the drugmakers hope that they will be approved after all-important phase 3 trials as early as the end of 2020.

READ: TikTok in talks to move global headquarters to London over Chinese tussle with US

A Sinovac representative revealed that his company has already completed the construction of a vaccine factory which will be able to produce 300 million doses of the vaccine annually. This is just as people at the trade fair on Monday, crowded around booths showing the potential game-changing vaccines.

The Chinese state media and officials are making attempts to show the progress on domestic vaccines as a sign of Chinese leadership and resilience in the face of an unprecedented health threat that has pummeled the global economy.

READ: EU to buy $478 million WHO COVID-19 vaccine for low and middle income countries

The Chinese President, Xi Jinping, in May, pledged to make any potential vaccine developed by China, a global public good.

Hotflex

These potential Chinese vaccines on display, are among the about 10 vaccine candidates globally, to enter the final phase of the trials ahead of regulatory approval.

Sinopharm said that it expects the antibodies from its jab to last between 1 and 3 years, although the final result will only be made available after the trials.

READ: Covid-19: US to start manufacturing vaccine for the virus in next 4 weeks 

A Chinese media outfit had last month reported that the price of the vaccines will not be high. The report quoted the Sinopharm’s Chairman as saying that every 2 doses of its vaccine should cost below $146, while also telling the media that he has already been injected with one of the candidate vaccines.

China’s official Xinhua news agency reported Monday that another vaccine candidate which is being developed by Chinese military scientists can deal with mutations in the coronavirus.

READ: FAAN in recruitment scandal as politicians hijack process

As of last month, about 5.7 billion doses of the vaccines under development around the world had been pre-ordered.

Jaiz bank

However, the World Health Organization has warned that widespread immunization against Covid-19 may not be on the cards until the middle of next year.

Chike Olisah is a graduate of accountancy with over 15 years working experience in the financial service sector. He has worked in research and marketing departments of three top commercial banks. Chike is a senior member of the Nairametrics Editorial Team. You may contact him via his email- [email protected]

1 Comment

1 Comment

    Leave a Reply

    Your email address will not be published.

    This site uses Akismet to reduce spam. Learn how your comment data is processed.

      





    Nairametrics | Company Earnings

    Access our Live Feed portal for the latest company earnings as they drop.